Johnson & Johnson (NYSE:JNJ) Shares Sold by Collaborative Wealth Managment Inc.

Collaborative Wealth Managment Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 16.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,089 shares of the company’s stock after selling 399 shares during the period. Collaborative Wealth Managment Inc.’s holdings in Johnson & Johnson were worth $328,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AGF Management Ltd. raised its position in shares of Johnson & Johnson by 49.8% in the fourth quarter. AGF Management Ltd. now owns 646,377 shares of the company’s stock valued at $101,313,000 after buying an additional 214,745 shares during the last quarter. Valley Wealth Managers Inc. lifted its position in Johnson & Johnson by 1.9% during the fourth quarter. Valley Wealth Managers Inc. now owns 119,311 shares of the company’s stock worth $18,701,000 after buying an additional 2,170 shares during the period. Cary Street Partners Investment Advisory LLC boosted its stake in Johnson & Johnson by 1.2% in the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 114,494 shares of the company’s stock worth $17,946,000 after buying an additional 1,381 shares during the last quarter. Buckingham Capital Management Inc. grew its holdings in Johnson & Johnson by 8.2% in the 4th quarter. Buckingham Capital Management Inc. now owns 11,585 shares of the company’s stock valued at $1,816,000 after buying an additional 882 shares during the period. Finally, Kinsale Capital Group Inc. lifted its holdings in shares of Johnson & Johnson by 36.3% during the 4th quarter. Kinsale Capital Group Inc. now owns 24,744 shares of the company’s stock worth $3,878,000 after acquiring an additional 6,587 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $151.36 on Wednesday. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The stock has a market cap of $364.28 billion, a P/E ratio of 9.44, a PEG ratio of 2.49 and a beta of 0.55. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The firm has a 50-day moving average of $152.63 and a two-hundred day moving average of $154.99.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same quarter last year, the firm earned $2.68 EPS. Johnson & Johnson’s quarterly revenue was up 2.3% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 10.64 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.28%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio is 29.68%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent analyst reports. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Bank of America reduced their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, May 6th. Finally, HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.

Check Out Our Latest Report on Johnson & Johnson

Insiders Place Their Bets

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.